Ultragenyx Pharmaceutical Financial Ratios
NASDAQ: RAREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
15.48+0.19 (+1.24%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ultragenyx Pharmaceutical ratio analysis
Ultragenyx Pharmaceutical earned a net margin of -85.4% in FY 2025, up from -101.6% a year earlier. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Ultragenyx Pharmaceutical financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price / sales | 3.46 | 6.71 | 8.10 | 8.92 | 16.22 | 31.08 | 23.48 | 41.56 | 753.82 | 20,927.48 |
| Price / book | — | 14.73 | 12.78 | 9.20 | 6.18 | 7.30 | 3.72 | 3.52 | 5.13 | 5.87 |
| Gross margin | — | — | — | — | — | — | — | 97.8% | 100.0% | — |
| Operating margin | -79.5% | -95.7% | -131.1% | -178.6% | -108.6% | -121.8% | -409.0% | -721.2% | -12,593.5% | -186,471.4% |
| Net margin | -85.4% | -101.6% | -139.9% | -194.7% | -129.2% | -68.8% | -388.3% | -383.7% | -11,567.3% | -184,867.7% |
| Free cash flow margin | -70.1% | -75.2% | -119.6% | -136.7% | -117.2% | -65.0% | -357.0% | -572.2% | -9,825.3% | -128,694.0% |
| Return on equity (ROE) | — | -223.1% | -220.7% | -201.0% | -49.2% | -16.2% | -61.6% | -32.5% | -78.8% | -51.9% |
| Return on assets (ROA) | -37.5% | -37.9% | -40.7% | -45.8% | -29.8% | -10.6% | -35.5% | -27.5% | -61.6% | -45.5% |
| Current ratio | 2.48 | 2.38 | 2.61 | 3.38 | 4.72 | 6.83 | 8.24 | 6.99 | 3.80 | 6.67 |
| Revenue growth | 20.2% | 29.0% | 19.5% | 3.4% | 29.7% | 161.3% | 101.4% | 1,871.5% | 1,863.9% | — |